Masterclass 1: The Unified Vaccine Platform: A Standardized Framework for Versatile and Rapid Animal Vaccine Development:

The Unified Vaccine Platform: A Standardized Framework for Versatile and Rapid Animal Vaccine Development:
Analogous to a Swiss Army knife, where a single standardized design supports multiple functions, the Unified Vaccine Platform (UVP) applies one coherent technological framework to a broad range of veterinary vaccine applications. The core of the UVP is an antigen capsule technology that enables end-to-end process standardization—from antigen design through regulatory submission to industrial-scale manufacturing—while preserving pathogen-specific immunogenicity. 

The UVP has been validated across seven vaccine programs targeting both enveloped and non-enveloped viruses, demonstrating robustness, transferability, and manufacturing compatibility. As a key case study, VeroBlue-3, a recombinant bluetongue virus serotype 3 vaccine, progressed from concept to EMA dossier completion within nine months, highlighting substantial acceleration over conventional inactivated virus vaccine development. 

Beyond supporting “traditional” vaccine programs, the platform directly addresses a major unmet need: the rapid generation of field-adapted vaccines targeting variants of highly mutating pathogens, as well as precisely geography-matched vaccines tailored to regional strain diversity. This capability is expected to impact pipeline design and lifecycle management across portfolios. 

This presentation will provide validation data, development workflows, and manufacturing performance of the UVP, and will outline how its standardized, recombinant approach differs from mRNA-based vaccines. By combining scientific versatility with predictable, scalable processes, the UVP targets high medical need and offers substantial economic potential through faster development, platform re-use, and more agile response to evolving pathogen landscapes.

Stefan Bennewitz (Verovaccines)